Pharmacokinetic and clinical studies were carried out with gatifloxacin (GFLX) in otorhinolaryngological infections.The results were as follows:<BR>1. The concentration of GFLX in the mucous membrane of the middle ear was 2.68-3.64μEg/g, in the mucous membrane of paranasal sinuses was 0.30-2.49μEg/g, and in the tonsils, 0.06-3.12μg/g.<BR>2. Clinical efficacy rates were 77.8%(28/36) in otitis media, 96.4%(27/28) in paranasal sinusitis, and 81.8%(18/22) in tonsillitis.Overall clinical efficacy was assessed as excellent in 48 cases, good in 33, fair in 10 and poor in 5, the efficacy rate being 84.4%(81/96).<BR>Bacteriological elimination rates were 85.7%(60/70) for Gram-positive bacteria and 88.9%(24/27) for Gram-negative bacteria. The rate for anaerobes was 100%(11/11).<BR>Side effects were observed in eight of 138 cases (5.8 %), but they were slight.<BR>Abnormal laboratory findings were recorded in 2 cases (2.1 %). All were mild in degree.<BR>From the above results, we conclude that GFLX is a useful drug for the treatment of otorhinolaryngological infections.
Japanese Journal of Chemotherapy 47 (Supplement2), 372-386, 1999
Japanese Society of Chemotherapy